Hepatic Proprotein Convertases Modulate HDL Metabolism [PDF]
Cell Metabolism, 2007 The risk of atherosclerosis is inversely associated with plasma levels of high-density lipoprotein cholesterol (HDL-C). However, HDL metabolism is incompletely understood, and there are few effective approaches to modulate HDL-C levels. Here we show that inhibition in the liver of the classical proprotein convertases (PCs), but not the atypical PCs S1P
Jin, Weijun +6 more
openaire +2 more sources
Proprotein Convertases and the Complement System
Frontiers in Immunology, 2022 Proteins destined for secretion - after removal of the signal sequence - often undergo further proteolytic processing by proprotein convertases (PCs). Prohormones are typically processed in the regulated secretory pathway, while most plasma proteins travel though the constitutive pathway.
József Dobó +3 more
openaire +3 more sources
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
JACC: Case Reports, 2020 Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with ...
Bruce A. Warden, PharmD +5 more
doaj +1 more source
Proprotein Convertase Subtilisin Kexin 9 Inhibitors [PDF]
Cardiology Clinics, 2018 High levels of low-density lipoprotein cholesterol (LDL-C) are directly associated with an increased risk of cardiovascular disease. Reducing LDL-C levels reduces the incidence of cardiovascular events. Several lipid-lowering approaches are available to achieve the LDL-C levels recommended by current guidelines, statins being the first-line therapy ...
A. Pirillo, A. L. Catapano
openaire +2 more sources
A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C. [PDF]
PLoS ONE, 2009 Furin represents a crucial member of secretory mammalian subtilase, the Proprotein Convertase (PC) or Proprotein Convertase Subtilisin/Kexin (PCSK) superfamily. It has been linked to cancer, tumorgenesis, viral and bacterial pathogenesis.
Ajoy Basak +6 more
doaj +1 more source
Proprotein Convertases Process Pmel17 during Secretion [PDF]
Journal of Biological Chemistry, 2011 Pmel17 is a melanocyte/melanoma-specific protein that traffics to melanosomes where it forms a fibrillar matrix on which melanin gets deposited. Before being cleaved into smaller fibrillogenic fragments the protein undergoes processing by proprotein convertases, a class of serine proteases that typically recognize the canonical motif RX(R/K)R↓.
Leonhardt, Ralf M. +3 more
openaire +2 more sources
Suppressor of Cytokine Signaling-3 (SOCS-3) induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) expression in hepatic HepG2 cell line [PDF]
, 2015 The suppressor of cytokine signaling (SOCS) proteins are negative regulators of the JAK/STAT pathway activated by proinflammatory cytokines, including the tumor necrosis factor (TNF-\u3b1).
Corsini, Alberto +7 more
core +2 more sources
Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
JACC: Case Reports, 2020 A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury.
June K. Pickett, MD +6 more
doaj +1 more source
Prediction of proprotein convertase cleavage sites [PDF]
Protein Engineering, Design and Selection, 2004 Many secretory proteins and peptides are synthesized as inactive precursors that in addition to signal peptide cleavage undergo post-translational processing to become biologically active polypeptides. Precursors are usually cleaved at sites composed of single or paired basic amino acid residues by members of the subtilisin/kexin-like proprotein ...
Peter, Duckert +2 more
openaire +2 more sources
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". [PDF]
, 2016 BackgroundProprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population.
Deeks, Steven +10 more
core +1 more source